Abdel-Rahman Nader, Kramer Mordechai R, Saute Milton, Raviv Yael, Fruchter Oren
The Pulmonary Division, Rabin Medical Center, Petach Tikva, Israel.
Eur J Cardiothorac Surg. 2014 May;45(5):854-8. doi: 10.1093/ejcts/ezt458. Epub 2013 Sep 15.
Bronchial stenosis is still a significant source of morbidity and mortality following lung transplantation (LTX) and often mandating placement of a bronchial stent. It has been suggested that although self-expanding metal stents offer excellent early palliation, their long-term complication rates are unacceptably high, and hence, their usage in many transplantation centres has been nearly abandoned. The aim of the study was to assess short- and long-term complication rates and survival in LTX patients with bronchial stenosis treated with insertion of self-expanding metal stents.
From January 1997 to March 2013, 435 patients underwent LTX (325 single-LTX and 110 bilateral LTX). Of 503 actual anastomoses at risk (derived by subtracting the number of anastomoses in 30 patients who died within 30 days of LTX), 60 airway complications (11.9%) in 47 patients required self-expanding metal stent insertion. We assessed the early results and long-term outcomes and survival compared with LTX patients in whom stents were not required.
The median follow-up period ranged from 1 to 132 (median 54) months. Immediate relief of symptoms was achieved in the vast majority of patients (95%). One-, three- and five-year survival in patients who required self-expanding metal stent placement were 77.7, 66.6 and 55.5%, respectively. The corresponding survival rates in LTX patients without stents were 69, 64.9 and 61.1% (P > 0.05).
Self-expanding metal stents are safe and effective tools in the management of airway complications post-LTX and provide immediate improvement in symptoms and pulmonary function tests in the vast majority of cases. The long-term complication rate is low, and mortality is similar to that in LTX patients who did not require stent insertion.
支气管狭窄仍是肺移植(LTX)后发病和死亡的重要原因,常需放置支气管支架。有人认为,尽管自膨式金属支架能提供良好的早期缓解效果,但其长期并发症发生率高得令人难以接受,因此,许多移植中心已几乎不再使用。本研究的目的是评估接受自膨式金属支架置入治疗的LTX合并支气管狭窄患者的短期和长期并发症发生率及生存率。
1997年1月至2013年3月,435例患者接受了LTX(325例单肺移植和110例双肺移植)。在503个实际存在风险的吻合口(通过减去30例LTX后30天内死亡患者的吻合口数量得出)中,47例患者出现60例气道并发症(11.9%),需要置入自膨式金属支架。我们评估了早期结果、长期结局及生存率,并与无需置入支架的LTX患者进行比较。
中位随访时间为1至132个月(中位54个月)。绝大多数患者(95%)症状立即得到缓解。需要置入自膨式金属支架的患者1年、3年和5年生存率分别为77.7%、66.6%和55.5%。未置入支架的LTX患者相应的生存率分别为69%、64.9%和61.1%(P>0.05)。
自膨式金属支架是治疗LTX后气道并发症的安全有效工具,在绝大多数情况下能立即改善症状和肺功能测试结果。长期并发症发生率低,死亡率与无需置入支架的LTX患者相似。